

# Are Plain Language Summaries of Health Economic Publications Needed for Patients and Non-expert Audiences?

Elizabeth Harvey,<sup>1</sup> Zoe Blumer,<sup>1</sup> Jon Carthy,<sup>1</sup> Suki Kandola,<sup>1</sup> Paola Kruger,<sup>2</sup> Kristyn Morgan,<sup>3</sup> Simon R. Stones,<sup>4</sup> and Karen Woolley<sup>5-7</sup>

<sup>1</sup>Curo, Envision Pharma Group, London, UK; <sup>2</sup>Patient Author, EUPATI, Rome, Italy; <sup>3</sup>Envision Pharma Group, Fairfield, CT, USA; <sup>4</sup>Patient Author, Collaboro Consulting, Manchester, UK; <sup>5</sup>University of Queensland, Brisbane, Queensland, Australia; <sup>6</sup>University of the Sunshine Coast, Maroochydore, Queensland, Australia; <sup>7</sup>Consultant, Envision Pharma Group, Sydney, Australia

## Background and Objective

- The importance of patient involvement in outcomes research and in assessing the value of medications is increasingly recognized. [1,2]
- This is further supported by the recent announcement of the ISPOR consensus definition of patient engagement in research<sup>3</sup>

Our research focused on better understanding:

1 Current involvement of patients in health technology assessment (HTA) and health economics and outcomes research (HEOR)

2 Unmet needs and key considerations for plain language summaries (PLS) of health economic publications to support patient involvement in HTA and HEOR

“The active, meaningful, and collaborative interaction between patients and researchers across all stages of the research process, where research decision-making is guided by patients’ contributions as partners, recognizing their specific experiences, values and expertise.”  
ISPOR definition of patient engagement in research – Harrington et al, 2020<sup>3</sup>

## Methods

### March 2020 Rapid evidence assessment

- Conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines
- Identified literature (January 2015 to March 2020, English language) on patient involvement in HTA and HEOR

### June 2020 Patient expert and health economist interviews

- Interviews among patient experts who had participated in HTA (n=4; Canada, Italy, UK, US) and health economist advisors to HTA (n=2; UK, US/Canada)
- An example PLS was developed for participants to review and consider key PLS criteria

### September/October 2020 Plain language “text + visuals” explanation (PLE) development and assessment

- Two PLEs were developed and reviewed by the patient experts and health economists who provided feedback on the PLS examples
- Additional feedback is being collected to optimize the PLEs. Additional relevant PLEs may be developed for inclusion in the HTA/HEOR PLS toolkit

### 2021 Plain language toolkit for HTA/HEOR PLS

- Further research is planned to develop and test an HTA/HEOR PLS toolkit and identify approaches to better integrate PLS within HTA and HEOR frameworks

## Results

### Rapid evidence assessment (REA)



- Across the identified publications, patient involvement in HTA and HEOR was considered important; however, significant challenges were identified, including communicating the purpose of HTA and HEOR, methodologies, and technical data to patient partners<sup>4</sup>

### Interviews

- Patient and health economist interview participants strongly supported patient involvement in HTA and HEOR, but highlighted similar challenges<sup>4</sup>
- Both the REA and interviews indicated that consistent use of PLS could help to facilitate patient contributions to HTA and HEOR by addressing communication challenges and creating equity with respect to other stakeholders
- In addition to patient-accessible language, using infographics and interpreting study data from the patient perspective were noted as important considerations for PLS

“It levels the playing field, and puts everyone on an equal footing so patients can speak with authority on what they have read. Levelling the playing field is crucial in this activity.”

Patient quote on the potential benefits of PLS in HEOR/HTA

### PLE: survey results

- Preliminary testing of the cost-effectiveness “text + visuals” PLE highlighted the need to not only provide clarity around technical terminology but also provide context on the purpose and utility of evaluating cost-effectiveness for healthcare decision-making
- The accompanying PLE “What is HTA?” was developed to help address this need. Continued testing of both PLEs is ongoing

### What next?

- Development of an HTA/HEOR plain language toolkit is ongoing, aligned with and augmenting an existing resource for PLS of peer-reviewed publications and congress abstracts<sup>5</sup>
- Further research is also required to identify approaches to better integrate PLS within HTA and HEOR frameworks

### Limitations

- This study represents preliminary research among a small sample of interviewees and survey respondents; further research is required to validate the findings


### REFERENCES:

1. Ung B, Khan Z, Willke R, et al. *Value & Outcomes Spotlight*. 2019;5(1):31-33. 2. Hunter A, Facey F, Thomas V, et al. *Front Med (Lausanne)*. 2018;5:231. 3. Harrington R, Hanna ML, Oehrlein EM, et al. *Value Health*. 2020;23(6):677-688. 4. Harvey E, Blumer Z, Carthy J, et al. *Value Health*. 2020;23(Suppl 2):S683. 5. Envision Pharma Group. Plain Language Summaries (PLS) of Publications Toolkit. URL: <https://www.envisionthepatient.com/plstoolkit/>. Accessed November 5, 2020.

## Conclusions

There is a need for consistent use of plain language communications to support patient involvement in HTA and HEOR

Our research identified several areas where the use of plain language communications of both health economic and other publications could remove barriers and help to facilitate patient involvement in HEOR and HTA



### What are plain language communications?

Any form of communication intended to convey technical information to a non technical audience, particularly patients

In developing a plain language toolkit for HEOR and HTA, we are developing 2 forms of plain language communications:

- PLS:** Brief “text + visuals” summaries of publications or individual studies.
- PLE:** Brief “text + visuals” explanations of technical methodologies or processes.

Access the QR codes or click the links below to view examples of 2 PLEs



What is HTA?  
<https://bit.ly/3oPPmN7>



How do we assess cost-effectiveness?  
<https://bit.ly/360Qftt>



Once you’ve reviewed the PLE examples, contribute to our continued research on the format and effectiveness of PLEs by taking our survey, linked below

<https://www.surveymonkey.co.uk/r/MJMTLB6>

### DISCLOSURES:

Envision Pharma Group (London, UK) provided limited financial compensation to interview participants for their time and funded expenses associated with the literature review. No payments were paid for authorship. EH, ZB, JC, SK, KM, and KW are employees and shareholders in Envision Pharma Group. SRS is an employee of Envision Pharma Group. PK received limited financial compensation from Envision Pharma Group for participation in the research interviews. All authors are advocates for greater involvement of patients as partners in medical research.

### ACKNOWLEDGMENTS:

The authors thank Catherine Rolland and Georgina Bowden, of Envision Pharma Group, for their contributions to the design and conduct of the rapid evidence assessment for this study.

### CONTACT AUTHOR

Elizabeth Harvey  
([elizabeth.harvey@envisionpharmagroup.com](mailto:elizabeth.harvey@envisionpharmagroup.com))

Previously presented at the European Meeting of ISMPP (Virtual), January 26-27, 2021.

Presented at the 17th Annual Meeting of the International Society for Medical Publication Professionals (Virtual), April 12-14, 2021.